Rigel Pharmaceuticals Inc cash flow statement
In fiscal 2025, Rigel Pharmaceuticals Inc's operations generated $75.7m of cash; it spent $0 on capital projects, leaving free cash flow of $75.7m.
Cash flow statement
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −76 | −78 | −59 | −42 | −52 | 6 | −74 | −6 | 31 | 76 | 79 |
| Depreciation and amortisation | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 |
| Stock-based pay | 7 | 6 | 8 | 9 | 7 | 9 | 12 | 9 | 12 | 13 | 16 |
| Capital spending | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −77 | −78 | −60 | −43 | −53 | 5 | −74 | −6 | 31 | 76 | 79 |
| Free cash flow after stock pay | −84 | −84 | −68 | −52 | −61 | −4 | −87 | −15 | 19 | 63 | 63 |
| Shares issued | 24 | 114 | 67 | — | — | — | — | — | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 22 | 15 | −1 | 31 | 24 | 22 | 3 | 31 |
| Depreciation and amortisation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Stock-based pay | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 7 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | 22 | 15 | −1 | 31 | 24 | 22 | 3 | 31 |
| Free cash flow after stock pay | 19 | 12 | −4 | 27 | 21 | 19 | −1 | 24 |
Compare with peers
- Harrow, Inc. cash flow
- Evolus, Inc. cash flow
- Aurora Cannabis Inc cash flow
- Vanda Pharmaceuticals Inc. cash flow
- Xeris Biopharma Holdings, Inc. cash flow
Head to head: HROW vs RIGLEOLS vs RIGLACB vs RIGL
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies